What is Ally-1?
Ally-1 is a combination treatment currently in Phase III clinical trials sponsored by Bristol-Myers Squibb. This treatment contains three medications: daclatasvir, sofosbuvir and ribavirin. The official title of this study is “A Phase 3 Evaluation of Daclatasvir, Sofosbuvir, and Ribavirin in Genotype 1-6 Chronic Hepatitis C Infection Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant”
As of April 2015 the trial results have shown this drug regimen cures 94% of post-liver transplant patients with hepatitis c and up to 94% of hepatitis c patients with cirrhosis. Additionally, the study has demonstrated that of the post-transplant patients, those with hepatitis c genotype 1a achieved cure rates of 97% and genotype 3 91%. More information can be found at Bristol-Myers Squibb’s website and ClinicalTrials.gov.
Last Updated: May 2015